AOD9604
A C-terminal growth hormone fragment studied for metabolic activity without the receptor engagement of the full hormone.
Synthetic tuftsin analogue
Selank
TP-7, Tuftsin analogue
A tuftsin-derived heptapeptide developed as an anxiolytic probe with a proline-glycine stabilising tail.
Research use only. This compound is supplied for laboratory
research and analytical use. It is not a medicine, not a supplement and
not for human or veterinary consumption. Several research peptides are prohibited in sport under WADA Section S2.
Chemical identity
Selank is the tetrapeptide tuftsin — an immunomodulatory fragment of the IgG heavy chain — extended at the C-terminus with a Pro-Gly-Pro tripeptide. That tail is a deliberate stabilisation strategy: proline-rich sequences resist aminopeptidase cleavage, and the extension raises the half-life of an otherwise very short-lived molecule.
The peptide was developed at the Institute of Molecular Genetics in Moscow. Most of its primary literature is Russian-language, which is the main practical obstacle for investigators working from it — several frequently cited results have never appeared in an English-language peer-reviewed journal.
Mechanism in research models
No single receptor has been identified. The reported activity is modulatory: rodent studies describe altered GABA-A receptor subunit expression, changes in serotonin turnover in the brainstem and hypothalamus, and effects on monoamine metabolism that differ from those of benzodiazepines.
A better-supported biochemical finding is inhibition of enkephalin degradation in plasma. By slowing enkephalinase activity, Selank extends the lifetime of endogenous opioid peptides — an indirect mechanism that would explain effects without direct receptor binding.
Interferon-gamma and IL-6 modulation has also been reported, consistent with the immunological origins of the tuftsin scaffold. Investigators should treat Selank as a compound with several weak effects rather than one strong one.
What the literature establishes
The rodent behavioural literature is reasonably consistent in reporting anxiolytic-type effects in standard paradigms — elevated plus maze, open field — without the motor impairment characteristic of benzodiazepines at equivalent behavioural effect.
Human data exist but come from small Russian clinical studies with designs that would not satisfy contemporary review standards. Sample sizes are small, blinding is often unclear, and independent replication outside Russia is essentially absent.
The honest position for a research plan: a plausible mechanism, a coherent animal literature, and clinical claims that have not been tested to modern standards. Treat Selank as an interesting probe, not an established agent.
Handling, reconstitution and storage
Storage and handling. Follow the approved conditions stated on the current lot-specific certificate of analysis and safety data sheet. The notes below describe general laboratory practice for this class of material and do not override the lot documentation. Contact research@apexscienceslabs.com before ordering if those documents are not available.
Lyophilised material is typically held sealed and desiccated at −20 °C; the validated condition is the one on the lot documentation. The proline-rich sequence gives Selank better enzymatic stability than most heptapeptides, but that is resistance to proteases, not to hydrolysis or moisture.
Highly water-soluble. Reconstitute with sterile or bacteriostatic water; dissolution is rapid and requires no solvent assistance.
Aliquot and freeze. Where intranasal delivery is being modelled, note that the formulation vehicle materially affects mucosal residence time and is not a neutral choice.
Analytical documentation
RP-HPLC purity, observed mass and net peptide content are the baseline. The free-acid C-terminus should be confirmed — amidated material is a different compound with different properties.
Selank has no aromatic residues beyond the arginine guanidinium, so UV detection at 214 nm is required rather than 280 nm. Certificates reporting purity by 280 nm absorbance for this sequence should be questioned.
References and authoritative sources
Chemical identity, regulatory status and anti-doping classification should be confirmed against primary sources rather than against this page. The records below are the ones to check first.
These are database and regulatory sources. Citations to specific primary papers are being added to this page as part of ongoing scientific review; until they appear, treat the mechanism and literature sections above as a summary to verify rather than a citation of record.
Editorial accountability
Written by Apex Sciences Labs editorial teamNot yet attributed to a named author
Scientific review Pending named reviewThis page has not yet been reviewed by a named, credentialled reviewer
Published August 26, 2026First publication of this page
Last reviewed September 22, 2026Identity, mechanism, literature limitations, handling statements and references.
Found an error? Report it to research@apexscienceslabs.com — see our corrections policy and editorial policy.
Sourcing partner
Avid Peptides supplies Selank and the rest of our peptide range
Apex Sciences Labs publishes the specification and handling documentation. Fulfilment for research peptides is handled by Avid Peptides, who supply lyophilised material against batch certificates with RP-HPLC purity and mass-spectrometry identity confirmation. Request the certificate for the specific batch before ordering — not a representative example.
Also in Peptides
Related compounds
PT-141
A cyclic melanocortin receptor agonist derived from the α-MSH scaffold, studied for centrally mediated effects.
Kisspeptin-10
The minimal active fragment of the KISS1 gene product, central to reproductive neuroendocrine research.
Next step
Enquire about Selank
Include the quantity and the intended laboratory application. We will respond with the current specification and the batch documentation available.